- IXICO, the brain health company, has been awarded a long-term contract from a leading global pharmaceutical company with a revenue value to IXICO of c. $1mper year. This project is for a large Phase II/III global clinical study in neurodegenerative disease which is expected to run over at least 7 years and will utilise IXICO's expertise in the collection and manipulation of magnetic resonance imaging (MRI) data including data from advanced MRI techniques.

IXICO will be working with specialist imaging centres at multiple global sites and will be using its TrialTracker and Assessa digital platforms to collect imaging data and measure and monitor changes in disease pathology in subjects enrolled in the study.

At 9:36am: [LON:IXI] IXICO plc share price was +3p at 31.5p

Story provided by